Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $385.26 million. The enterprise value is $208.93 million.
| Market Cap | 385.26M |
| Enterprise Value | 208.93M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 16.57 million shares outstanding. The number of shares has increased by 16.72% in one year.
| Current Share Class | 16.57M |
| Shares Outstanding | 16.57M |
| Shares Change (YoY) | +16.72% |
| Shares Change (QoQ) | +49.79% |
| Owned by Insiders (%) | 0.96% |
| Owned by Institutions (%) | 53.38% |
| Float | 10.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.99 |
| Forward PS | 11.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.12
| Current Ratio | 3.12 |
| Quick Ratio | 3.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.85 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.32% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -69.82% |
| Weighted Average Cost of Capital (WACC) | 20.23% |
| Revenue Per Employee | $748,932 |
| Profits Per Employee | -$1.15M |
| Employee Count | 133 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -115,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +170.63% in the last 52 weeks. The beta is 1.52, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | +170.63% |
| 50-Day Moving Average | 28.59 |
| 200-Day Moving Average | 20.40 |
| Relative Strength Index (RSI) | 39.32 |
| Average Volume (20 Days) | 357,584 |
Short Selling Information
The latest short interest is 1.65 million, so 9.97% of the outstanding shares have been sold short.
| Short Interest | 1.65M |
| Short Previous Month | 1.36M |
| Short % of Shares Out | 9.97% |
| Short % of Float | 16.04% |
| Short Ratio (days to cover) | 3.51 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $99.61 million and -$153.60 million in losses. Loss per share was -$15.87.
| Revenue | 99.61M |
| Gross Profit | -51.77M |
| Operating Income | -87.10M |
| Pretax Income | -153.72M |
| Net Income | -153.60M |
| EBITDA | -112.81M |
| EBIT | -119.51M |
| Loss Per Share | -$15.87 |
Balance Sheet
The company has $202.56 million in cash and $13.63 million in debt, with a net cash position of $188.93 million or $11.40 per share.
| Cash & Cash Equivalents | 202.56M |
| Total Debt | 13.63M |
| Net Cash | 188.93M |
| Net Cash Per Share | $11.40 |
| Equity (Book Value) | -66.89M |
| Book Value Per Share | -4.04 |
| Working Capital | 150.16M |
Cash Flow
In the last 12 months, operating cash flow was -$151.61 million and capital expenditures -$532,000, giving a free cash flow of -$152.14 million.
| Operating Cash Flow | -151.61M |
| Capital Expenditures | -532,000 |
| Depreciation & Amortization | 6.70M |
| Net Borrowing | n/a |
| Free Cash Flow | -152.14M |
| FCF Per Share | -$9.18 |
Margins
Gross margin is -51.97%, with operating and profit margins of -87.44% and -154.21%.
| Gross Margin | -51.97% |
| Operating Margin | -87.44% |
| Pretax Margin | -154.32% |
| Profit Margin | -154.21% |
| EBITDA Margin | -113.25% |
| EBIT Margin | -119.98% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.72% |
| Shareholder Yield | -16.72% |
| Earnings Yield | -38.61% |
| FCF Yield | -38.24% |
Analyst Forecast
The average price target for Sutro Biopharma is $47.75, which is 105.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.75 |
| Price Target Difference | 105.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | -40.93% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Sutro Biopharma has an Altman Z-Score of -5.69 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.69 |
| Piotroski F-Score | 4 |